Pharmacology

Action Mechanism of Action Reference
ANTAGONIST Programmed cell death protein 1 antagonist FDA

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Endometrial Neoplasms 4 D016889 ClinicalTrials
Ovarian Neoplasms 3 D010051 ClinicalTrials
Ovarian Neoplasms 3 D010051 ClinicalTrials
Rectal Neoplasms 2 D012004 ClinicalTrials
Liver Neoplasms 2 D008113 ClinicalTrials
Uterine Cervical Neoplasms 2 D002583 ClinicalTrials
Small Cell Lung Carcinoma 2 D055752 ClinicalTrials
Mesothelioma 2 D008654 ClinicalTrials
Sarcoma 2 D012509 ClinicalTrials
Melanoma 2 D008545 ClinicalTrials
Head and Neck Neoplasms 2 D006258 ClinicalTrials
Uterine Cervical Neoplasms 2 D002583 ClinicalTrials
Carcinoma, Pancreatic Ductal 2 D021441 ClinicalTrials
Pancreatic Neoplasms 2 D010190 ClinicalTrials
Carcinoma, Non-Small-Cell Lung 2 D002289 ClinicalTrials
Hemangiosarcoma 2 D006394 ClinicalTrials
Breast Neoplasms 2 D001943 ClinicalTrials
Hereditary Breast and Ovarian Cancer Syndrome 2 D061325 ClinicalTrials
Multiple Myeloma 1 D009101 ClinicalTrials

Cross References

Resources Reference
ChEMBL CHEMBL4298124
FDA SRS P0GVQ9A4S5